IRIS
CAROTENUTO, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.034
NA - Nord America 4.688
EU - Europa 3.987
SA - Sud America 726
AF - Africa 161
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 4
Totale 15.617
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.470
SG - Singapore 2.502
RU - Federazione Russa 1.637
CN - Cina 1.240
VN - Vietnam 1.089
IT - Italia 938
BR - Brasile 548
HK - Hong Kong 504
DE - Germania 398
FR - Francia 205
NL - Olanda 193
IN - India 145
GB - Regno Unito 125
CA - Canada 124
JP - Giappone 112
FI - Finlandia 107
KR - Corea 86
IE - Irlanda 83
UA - Ucraina 74
BD - Bangladesh 70
AR - Argentina 66
ZA - Sudafrica 53
MX - Messico 45
ES - Italia 39
CI - Costa d'Avorio 38
PH - Filippine 36
PL - Polonia 36
SE - Svezia 36
TH - Thailandia 35
IQ - Iraq 33
EC - Ecuador 30
TR - Turchia 26
AT - Austria 23
ID - Indonesia 23
VE - Venezuela 20
CO - Colombia 19
LT - Lituania 19
PK - Pakistan 18
TW - Taiwan 16
BE - Belgio 15
SA - Arabia Saudita 15
CL - Cile 13
JO - Giordania 13
MA - Marocco 12
MY - Malesia 12
PY - Paraguay 12
TN - Tunisia 12
CZ - Repubblica Ceca 10
NP - Nepal 10
AE - Emirati Arabi Uniti 9
JM - Giamaica 9
EG - Egitto 8
KE - Kenya 8
PE - Perù 8
AU - Australia 7
DZ - Algeria 7
CR - Costa Rica 6
DO - Repubblica Dominicana 6
NI - Nicaragua 6
NZ - Nuova Zelanda 6
BO - Bolivia 5
ET - Etiopia 5
GR - Grecia 5
IR - Iran 5
MK - Macedonia 5
PT - Portogallo 5
RS - Serbia 5
BG - Bulgaria 4
GT - Guatemala 4
HN - Honduras 4
HR - Croazia 4
IL - Israele 4
MN - Mongolia 4
OM - Oman 4
PA - Panama 4
AM - Armenia 3
CU - Cuba 3
LV - Lettonia 3
MD - Moldavia 3
UY - Uruguay 3
UZ - Uzbekistan 3
AL - Albania 2
AZ - Azerbaigian 2
BB - Barbados 2
CH - Svizzera 2
GA - Gabon 2
GD - Grenada 2
GE - Georgia 2
GY - Guiana 2
LB - Libano 2
NG - Nigeria 2
NO - Norvegia 2
QA - Qatar 2
RE - Reunion 2
SI - Slovenia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
Totale 15.586
Salva come PNG Salva come JPEG
Città #
Singapore 1.238
San Jose 808
Ashburn 510
Hong Kong 474
Moscow 424
Hefei 401
Beijing 330
Ho Chi Minh City 325
Chandler 309
Hanoi 250
Santa Clara 235
Naples 203
Los Angeles 160
Amsterdam 145
Lauterbourg 110
Tokyo 104
The Dalles 96
Munich 86
Council Bluffs 78
Millbury 77
New York 77
Dallas 76
Seoul 69
São Paulo 63
Buffalo 57
Des Moines 57
Milan 55
Boston 52
Da Nang 50
Napoli 50
Redondo Beach 49
Frankfurt am Main 41
Denver 40
Montreal 40
Nanjing 39
Seattle 38
Haiphong 37
Helsinki 37
Princeton 37
Lawrence 36
Rome 34
Krefeld 33
Dublin 31
Orem 31
Chicago 30
Toronto 29
Warsaw 29
Johannesburg 28
Norwalk 28
London 26
Stockholm 26
Dong Ket 24
Falkenstein 24
Houston 23
Turku 23
Chennai 22
Atlanta 21
Brooklyn 21
Nuremberg 19
Phoenix 19
Mexico City 18
Lappeenranta 17
Pune 17
Tianjin 17
Wilmington 17
Boardman 16
Rio de Janeiro 16
Biên Hòa 15
Ottawa 15
Poplar 15
Rottweil 15
Baghdad 14
Düsseldorf 14
Paris 14
Bangkok 13
Can Tho 13
Curitiba 13
San Francisco 13
Ankara 12
Belo Horizonte 12
Cava De' Tirreni 12
Mumbai 12
Thái Nguyên 12
Bari 11
Manchester 11
Amman 10
Brasília 10
Bến Tre 10
Catania 10
Hải Dương 10
Kolkata 10
Quito 10
Shanghai 10
Brussels 9
Formia 9
Nanchang 9
Turin 9
Vienna 9
Campinas 8
Cape Town 8
Totale 8.379
Salva come PNG Salva come JPEG
Nome #
AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature 280
Uric acid: a potential biomarker of multiple sclerosis and of its disability 209
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis 185
ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis 183
The use of medical-grade cannabis in patients non-responders to Nabiximols 168
2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis 168
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression 165
Assessment of neuroactive steroids in cerebrospinal fluid comparing acute relapse and stable disease in relapsing-remitting multiple sclerosis 165
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 163
Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis 161
The effects of mechanical focal vibration on walking impairment in multiple sclerosis patients: A randomized, double-blinded vs placebo study 160
Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 158
Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis 156
Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study 155
Inhibition of oligodendrocyte differentiation by immunoglobulin purified from serum of multiple sclerosis patients during relapse 152
Normative values of the Rao’s Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education 150
Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis 149
Grey/white matter ratio at diagnosis, and the risk of 10-year multiple sclerosis progression 148
Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex(®) 147
Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod 146
Tango classes in people with Multiple Sclerosis (PwMS): Impact on motor and non-motor functions 145
Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy) 145
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells 144
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients 144
Quality of life and cognitive function in pediatric and young multiple sclerosis patients: a cross-sectional study 143
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a 143
Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience 143
Concomitant diagnosis of multiple sclerosis and human immunodeficiency virus (HIV) infection: case report and the review of literature 142
A real-world study of alemtuzumab in a cohort of Italian patients 142
Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy 142
Pragmatic abilities in multiple sclerosis: The contribution of the temporo-parietal junction 142
Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis 142
Cognitive trajectories in multiple sclerosis: a long-term follow-up study 142
Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020 141
Neurofilament light chain and Alzheimer pathology biomarkers in elderly people with multiple sclerosis 141
Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study 141
Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis 139
Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis 139
Biochemical parameters alterations in multiple sclerosis: a longitudinal study and review of the literature. 139
Clinical correlates of R1 relaxometry and magnetic susceptibility changes in multiple sclerosis: a multi-parameter quantitative MRI study of brain iron and myelin 138
ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial 138
Retinal vascular density in multiple sclerosis: a one year follow up 137
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis 136
Being highly sensitive person negatively impacts on cognitive and psychosocial fatigue in multiple sclerosis patients: A cross-sectional, monocenter study 135
COVID-19 pandemic and mental distress in Multiple Sclerosis: implications for clinical management 133
Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors 132
Exploring the relation between reserve and fatigue in multiple sclerosis 131
Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing–Remitting Multiple Sclerosis 131
Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment 130
Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study 130
A retrospective exploratory analysis on cardiovascular risk and cognitive dysfunction in multiple sclerosis 130
Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies 130
Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions 127
Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis 127
Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications 126
Communication in Multiple Sclerosis: Pragmatic Deficit and its Relation with Cognition and Social Cognition 126
Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis 126
Correction to: Concomitant diagnosis of multiple sclerosis and human immunodeficiency virus (HIV) infection: case report and the review of literature 125
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis 124
Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review 122
Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years 121
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate. 121
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 121
Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg 120
The independent contribution of brain, spinal cord and gadolinium MRI in treatment decision in multiple sclerosis: A population-based retrospective study 120
Dysphagia assessment in patients with multiple sclerosis - an additional piece to disability burden 119
Olfactory function and cognition in relapsing–remitting and secondary-progressive multiple sclerosis 119
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study 118
Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis 118
Identifying neuropsychological phenotypes in multiple sclerosis using latent profile analysis 117
Epidemiology of multiple sclerosis in the Campania Region (Italy): Derivation and validation of an algorithm to calculate the 2015-2020 incidence 117
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. 117
Teeth loss after teriflunomide treatment: Casual or causal? A short case series 117
Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study 117
Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression 116
[18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis 115
Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data 115
Anatomical and functional retinal changes in multiple sclerosis 113
Can people with multiple sclerosis actually understand what they read in the Internet age? 111
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study 111
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis 110
A longitudinal real-life comparison study of natalizumab and fingolimod 110
A 8-year retrospective cohort study comparing Interferon-beta formulations for relapsing-remitting multiple sclerosis 110
Integration of the expanded disability status scale with ambulation, visual and cognitive tests 109
A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing-remitting multiple sclerosis 109
Assessment of retinal vascular network in amnestic mild cognitive impairment by optical coherence tomography angiography 108
The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis 108
Association between CD20+ T lymphocytes and neuropsychological findings in multiple sclerosis 107
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 105
Epidemiological and Immune Profile Analysis of Italian Subjects with Endometriosis and Multiple Sclerosis 104
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study 104
Sexual dysfunction in people with multiple sclerosis: The role of disease severity, illness perception, and depression 104
Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia 102
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy 102
Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications 98
Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 Trials 98
Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study 97
The Framingham cardiovascular risk score in multiple sclerosis 94
Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy) 92
Prevalence and Incidence of Paramagnetic Rim Lesions in Multiple Sclerosis: A Systematic Review and Meta-Analysis 92
Totale 13.207
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.577
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.577
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022467 8 1 4 6 11 36 8 17 58 34 105 179
2022/20231.000 81 87 20 43 87 125 152 53 152 132 45 23
2023/2024678 32 96 84 56 41 85 17 71 21 17 101 57
2024/20254.047 182 179 32 72 132 251 432 279 246 431 1.414 397
2025/20268.761 836 743 888 908 1.474 291 884 613 1.057 631 244 192
2026/2027104 104 0 0 0 0 0 0 0 0 0 0 0
Totale 15.985